secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001213900-25-019437
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed enters royalty purchase on Gloperba/Elyxyb and rest-of-world license for Gloperba
--------------------------------------------------------------------------------

- Oramed gains right to 50% of 4% net sales royalty on Gloperba and Elyxyb worldwide (effectively 2% of net sales).
- Oramed via RoyaltyVest Ltd gets exclusive rest-of-world license for Gloperba; net revenue split 50/50 with Scilex.
- Agreements executed Feb 28, 2025 as part of deferral on $50M Scilex convertible notes due Oct 2026.
- Oramed transferred 50% of RoyaltyVest shares to other investors; retains right to designate half the board.
- Subordination Agreement grants first-priority lien on royalty collateral to Oramed and other purchasers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025019437/0001213900-25-019437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025019437/ea0232721-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-019437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer